Contrast media in patients with kidney disease: An update

REFERENCES

1. ↵
   1. Bartels ED,
   2. Brun GC,
   3. Gammeltoft A,
   4. Gjørup PA

   . Acute anuria following intravenous pyelography in a patient with myelomatosis. Acta Med Scand 1954; 150(4):297–302. doi:10.1111/j.0954-6820.1954.tb18632.x

   OpenUrlCrossRefPubMed
2. ↵
   1. Parfrey PS,
   2. Griffiths SM,
   3. Barrett BJ, et al

   . Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. N Engl J Med 1989; 320(3):143–149. doi:10.1056/NEJM198901193200303

   OpenUrlCrossRefPubMed
3. ↵
   1. Hou SH,
   2. Bushinsky DA,
   3. Wish JB,
   4. Cohen JJ,
   5. Harrington JT

   . Hospital-acquired renal insufficiency: a prospective study. Am J Med 1983; 74(2):243–248. doi:10.1016/0002-9343(83)90618-6

   OpenUrlCrossRefPubMed
4. ↵
   1. McCullough PA,
   2. Adam A,
   3. Becker CR, et al

   . Epidemiology and prognostic implications of contrast-induced nephropathy. Am J Cardiol 2006; 98(6A):5K–13K. doi:10.1016/j.amjcard.2006.01.019

   OpenUrlCrossRefPubMed
5. ↵
   1. Khwaja A

   . KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 2012; 120(4):c179–c184. doi:10.1159/000339789

   OpenUrlCrossRefPubMed
6. ↵
   1. McCullough PA,
   2. Adam A,
   3. Becker CR, et al

   . Risk prediction of contrast-induced nephropathy. Am J Cardiol 2006; 98(6A):27K–36K. doi:10.1016/j.amjcard.2006.01.022

   OpenUrlCrossRefPubMed
7. ↵
   1. Stratta P,
   2. Bozzola C,
   3. Quaglia M

   . Pitfall in nephrology: contrast nephropathy has to be differentiated from renal damage due to atheroembolic disease. J Nephrol 2012; 25(3):282–289. doi:10.5301/jn.5000093

   OpenUrlCrossRefPubMed
8. ↵
   1. Devireddy C,
   2. Hiremath S

   . Acute kidney injury after transcatheter aortic valve replacement. Circ Cardiovasc Interv 2018; 11(8):e007135. doi:10.1161/CIRCINTERVENTIONS.118.007135

   OpenUrlCrossRef
9. ↵
   1. Andò G,
   2. Gragnano F,
   3. Calabrò P,
   4. Valgimigli M

   . Radial vs femoral access for the prevention of acute kidney injury (AKI) after coronary angiography or intervention: a systematic review and meta-analysis. Catheter Cardiovasc Interv 2018; 92(7):E518–E526. doi:10.1002/ccd.27903

   OpenUrlCrossRefPubMed
10. ↵
    1. Mehran R,
    2. Dangas GD,
    3. Weisbord SD

    . Contrast-associated acute kidney injury. N Engl J Med 2019; 380(22):2146–2155. doi:10.1056/NEJMra1805256

    OpenUrlCrossRefPubMed
11. ↵
    1. McDonald RJ,
    2. McDonald JS,
    3. Bida JP, et al

    . Intravenous contrast material-induced nephropathy: causal or coincident phenomenon? Radiology 2013; 267(1):106–118. doi:10.1148/radiol.12121823

    OpenUrlCrossRefPubMed
12. ↵
    1. Chertow GM,
    2. Normand SLT,
    3. McNeil BJ

    . “Renalism”: inappropriately low rates of coronary angiography in elderly individuals with renal insufficiency”. J Am Soc Nephrol 2004; 15(9):2462–2468. doi:10.1097/01.ASN.0000135969.33773.0B

    OpenUrlAbstract/FREE Full Text
13. ↵
    1. Davenport MS,
    2. Khalatbari S,
    3. Cohan RH,
    4. Dillman JR,
    5. Myles JD,
    6. Ellis JH

    . Contrast material-induced nephrotoxicity and intravenous low-osmolality iodinated contrast material: risk stratification by using estimated glomerular filtration rate. Radiology 2013; 268(3):719–728. doi:10.1148/radiol.13122276

    OpenUrlCrossRefPubMed
14. ↵
    1. McDonald JS,
    2. McDonald RJ,
    3. Carter RE,
    4. Katzberg RW,
    5. Kallmes DF,
    6. Williamson EE

    . Risk of intravenous contrast material-mediated acute kidney injury: a propensity score-matched study stratified by baseline-estimated glomerular filtration rate. Radiology 2014; 271(1):65–73. doi:10.1148/radiol.13130775

    OpenUrlCrossRefPubMed
15. ↵
    1. Hinson JS,
    2. Ehmann MR,
    3. Fine DM, et al

    . Risk of acute kidney injury after intravenous contrast media administration. Ann Emerg Med 2017; 69(5):577–586.e4. doi:10.1016/j.annemergmed.2016.11.021

    OpenUrlCrossRefPubMed
16. ↵
    1. Hiremath S,
    2. Velez JCQ

    . Preventing a nonexistent entity: the curious case of contrast and acute kidney injury. Curr Opin Nephrol Hypertens 2020; 29(1):152–160. doi:10.1097/MNH.0000000000000562

    OpenUrlCrossRef
17. ↵
    1. Rudnick MR,
    2. Leonberg-Yoo AK,
    3. Litt HI,
    4. Cohen RM,
    5. Hilton S,
    6. Reese PP

    . The controversy of contrast-induced nephropathy with intravenous contrast: what Is the risk? Am J Kidney Dis 2020; 75(1):105–113. doi:10.1053/j.ajkd.2019.05.022

    OpenUrlCrossRefPubMed
18. ↵
    1. Ghumman SS,
    2. Weinerman J,
    3. Khan A, et al

    . Contrast induced-acute kidney injury following peripheral angiography with carbon dioxide versus iodinated contrast media: a meta-analysis and systematic review of current literature. Catheter Cardiovasc Interv 2017; 90(3):437–448. doi:10.1002/ccd.27051

    OpenUrlCrossRef
19. ↵
    1. Chaudhury P,
    2. Armanyous S,
    3. Harb SC, et al

    . Intra-arterial versus intravenous contrast and renal injury in chronic kidney disease: a propensity-matched analysis. Nephron 2019; 141(1):31–40. doi:10.1159/000494047

    OpenUrlCrossRef
20. ↵
    1. Solomon R,
    2. Werner C,
    3. Mann D,
    4. D’elia J,
    5. Silva P

    . Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994; 331(21):1416–1420. doi:10.1056/NEJM199411243312104

    OpenUrlCrossRefPubMed
21. ↵
    1. Mueller C,
    2. Buerkle G,
    3. Buettner HJ, et al

    . Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002; 162(3):329–336. doi:10.1001/archinte.162.3.329

    OpenUrlCrossRefPubMed
22. ↵
    1. Nijssen EC,
    2. Rennenberg RJ,
    3. Nelemans PJ, et al

    . Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial. Lancet 2017; 389(10076):1312–1322. doi:10.1016/S0140-6736(17)30057-0

    OpenUrlCrossRefPubMed
23. ↵
    1. Timal RJ,
    2. Kooiman J,
    3. Sijpkens YWJ, et al

    . Effect of no prehydration vs sodium bicarbonate prehydration prior to contrast-enhanced computed tomography in the prevention of postcontrast acute kidney injury in adults with chronic kidney disease: the Kompas randomized clinical trial. JAMA Intern Med 2020; 180(4):533–541. doi:10.1001/jamainternmed.2019.7428

    OpenUrlCrossRef
24. ↵
    1. Weisbord SD,
    2. Gallagher M,
    3. Jneid H, et al

    . Outcomes after angiography with sodium bicarbonate and acetylcysteine. N Engl J Med 2018; 378(7):603–614. doi:10.1056/NEJMoa1710933

    OpenUrlCrossRefPubMed
25. ↵
    1. Berwanger O

    . Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-induced nephropathy Trial (ACT). Circulation 2011; 124(11):1250–1259. doi:10.1161/CIRCULATIONAHA.111.038943

    OpenUrlAbstract/FREE Full Text
26. ↵
    1. Bargman JM,
    2. Thorpe KE,
    3. Churchill DN

    . Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol 2001;(10):2158–2162. pmid:11562415

    OpenUrlAbstract/FREE Full Text
27. ↵
    1. Shemin D,
    2. Bostom AG,
    3. Laliberty P,
    4. Dworkin LD

    . Residual renal function and mortality risk in hemodialysis patients. Am J Kidney Dis 2001; 38(1):85–90. doi:10.1053/ajkd.2001.25198

    OpenUrlCrossRefPubMed
28. ↵
    1. Davenport MS,
    2. Perazella MA,
    3. Yee J, et al

    . Use of intravenous iodinated contrast media in patients with kidney disease: consensus statements from the American College of Radiology and the National Kidney Foundation. Radiology 2020; 294(3):660–668. doi:10.1148/radiol.2019192094

    OpenUrlCrossRef
29. ↵
    1. Cowper SE,
    2. Bucala R,
    3. Leboit PE

    . Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis—setting the record straight. Semin Arthritis Rheum 2006; 35(4):208–210. doi:10.1016/j.semarthrit.2005.09.005

    OpenUrlCrossRefPubMed
30. ↵
    1. Cowper SE,
    2. Robin HS,
    3. Steinberg SM,
    4. Su LD,
    5. Gupta S,
    6. LeBoit PE

    . Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000; 356(9234):1000–1001. doi:10.1016/S0140-6736(00)02694-5

    OpenUrlCrossRefPubMed
31. ↵
    1. Grobner T

    . Gadolinium—a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006; 21(4):1104–1108. doi:10.1093/ndt/gfk062

    OpenUrlCrossRefPubMed
32. ↵
    1. Marckmann P,
    2. Skov L,
    3. Rossen K, et al

    . Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006; 17(9):2359–2362. doi:10.1681/ASN.2006060601

    OpenUrlAbstract/FREE Full Text
33. ↵
    1. Mendoza FA,
    2. Artlett CM,
    3. Sandorfi N,
    4. Latinis K,
    5. Piera-Velazquez S,
    6. Jimenez SA

    . Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum 2006; 35(4):238–249. doi:10.1016/j.semarthrit.2005.08.002

    OpenUrlCrossRefPubMed
34. ↵
    1. Jiménez SA,
    2. Artlett CM,
    3. Sandorfi N, et al

    . Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor B1 expression in affected skin. Arthritis Rheum 2004; 50(8):2660–2666. doi:10.1002/art.20362

    OpenUrlCrossRefPubMed
35. ↵
    1. Wermuth PJ,
    2. Del Galdo F,
    3. Jiménez SA

    . Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents. Arthritis Rheum 2009; 60(5):1508–1518. doi:10.1002/art.24471

    OpenUrlCrossRefPubMed
36. ↵
    1. Boyd AS,
    2. Zic JA,
    3. Abraham JL

    . Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 2007; 56(1):27–30. doi:10.1016/j.jaad.2006.10.048.

    OpenUrlCrossRefPubMed
37. ↵
    1. Thomsen HS

    . Nephrogenic systemic fibrosis: history and epidemiology. Radiol Clin North Am 2009; 47(5):827–831, vi. doi:10.1016/j.rcl.2009.05.003

    OpenUrlCrossRefPubMed
38. ↵
    1. Stenver DI

    . Pharmacovigilance: what to do if you see an adverse reaction and the consequences. Eur J Radiol 2008; 66(2):184–186. doi:10.1016/j.ejrad.2008.02.009

    OpenUrlCrossRefPubMed
39. ↵
    1. US Food and Drug Administration

    . FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warnings. Accessed September 10, 2020. https://www.fda.gov/media/109825/download
40. ↵
    1. European Medicines Agency

    . Assessment report for gadolinium-containing contrast agents. Accessed September 10, 2020. https://www.ema.europa.eu/en/documents/referral/gadolinium-h-31-1097-assessment-report_en.pdf
41. ↵
    1. ACR Committee on Drugs and Contrast Media

    . ACR Manual on Contrast Media. American College of Radiology: 2020. Accessed September 10, 2020. https://www.acr.org/-/media/ACR/Files/Clinical-Resources/Contrast_Media.pdf
42. ↵
    1. Thomsen HS,
    2. Morcos SK,
    3. Almén T, et al

    . Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol 2013; 23(2):307–218. doi:10.1007/s00330-012-2597-9

    OpenUrlCrossRefPubMed
43. ↵
    1. Okada S,
    2. Katagiri K,
    3. Kumazaki T,
    4. Yokoyama H

    . Safety of gadolinium contrast agent in hemodialysis patients. Acta Radiol 2001; 42(3):339–341. pmid:11350296

    OpenUrlCrossRefPubMed
44. ↵
    1. Endrikat J,
    2. Dohanish S,
    3. Schleyer N,
    4. Schwenke S,
    5. Agarwal S,
    6. Balzer T

    . 10 Years of nephrogenic systemic fibrosis: a comprehensive analysis of nephrogenic systemic fibrosis reports received by a pharmaceutical company from 2006 to 2016. Invest Radiol 2018; 53(9):541–550. doi:10.1097/RLI.0000000000000462

    OpenUrlCrossRefPubMed
45. ↵
    1. Niendorf HP,
    2. Dinger JC,
    3. Haustein J,
    4. Cornelius I,
    5. Alhassan A,
    6. Clauß W

    . Tolerance data of Gd-DTPA: a review. Eur J Radiol 1991; 13(1):15–20. doi:10.1016/0720-048x(91)90049-2

    OpenUrlCrossRefPubMed
46. ↵
    1. Hammer FD,
    2. Goffette PP,
    3. Malaise J,
    4. Mathurin P

    . Gadolinium dimeglumine: an alternative contrast agent for digital subtraction angiography. Eur Radiol 1999; 9(1):128–136. doi:10.1007/s003300050643.

    OpenUrlCrossRefPubMed
47. ↵
    1. Gibby WA,
    2. Gibby KA,
    3. Gibby WA

    . Comparison of Gd DTPA-BMA (Omniscan) versus Gd HP-DO3A (ProHance) retention in human bone tissue by inductively coupled plasma atomic emission spectroscopy. Invest Radiol 2004; 39(3):138–142. doi:10.1097/01.rli.0000112789.57341.01

    OpenUrlCrossRefPubMed
48. ↵
    1. Schieda N,
    2. Blaichman JI,
    3. Costa AF, et al

    . Gadolinium-based contrast agents in kidney disease: comprehensive review and clinical practice guideline issued by the Canadian Association of Radiologists. Can Assoc Radiol J 2018; 69(2):136–150. doi:10.1016/j.carj.2017.11.002

    OpenUrlCrossRef
49. ↵
    1. Hao D,
    2. Ai T,
    3. Goerner F,
    4. Hu X,
    5. Runge VM,
    6. Tweedle M

    . MRI contrast agents: basic chemistry and safety. J Magn Reson Imaging 2012; 36(5):1060–1071. doi:10.1002/jmri.23725

    OpenUrlCrossRefPubMed
50. ↵
    1. Attari H,
    2. Cao Y,
    3. Elmholdt TR,
    4. Zhao Y,
    5. Prince MR

    . A systematic review of 639 patients with biopsy-confirmed nephrogenic systemic fibrosis. Radiology 2019; 292(2):376–386. doi:10.1148/radiol.2019182916

    OpenUrlCrossRefPubMed
51. ↵
    1. Balogh EP,
    2. Miller BT,
    3. Ball JR

    , eds. Improving Diagnosis in Health Care. Washington, DC: National Academies Press, 2016.
52. ↵
    1. Woolen SA,
    2. Shankar PR,
    3. Gagnier JJ,
    4. MacEachern MP,
    5. Singer L,
    6. Davenport MS

    . Risk of nephrogenic systemic fibrosis in patients with stage 4 or 5 chronic kidney disease receiving a group II gadolinium-based contrast agent: a systematic review and meta-analysis. JAMA Intern Med 2020; 180(2):223–230. doi:10.1001/jamainternmed.2019.5284

    OpenUrlCrossRefPubMed
53. ↵
    1. Davenport MS,
    2. Cohan RH,
    3. Ellis JH

    . Contrast media controversies in 2015: imaging patients with renal impairment or risk of contrast reaction. Am J Roentgenol 2015; 204(6):1174–1181. doi:10.2214/AJR.14.14259

    OpenUrlCrossRef
54. ↵
    1. Katayama H,
    2. Yamaguchi K,
    3. Kozuka T,
    4. Takashima T,
    5. Seez P,
    6. Matsuura K

    . Adverse reactions to ionic and nonionic contrast media. a report from the Japanese Committee on the Safety of Contrast Media. Radiology 1990; 175(3):621–628. doi:10.1148/radiology.175.3.2343107

    OpenUrlCrossRefPubMed
55. ↵
    1. Behzadi AH,
    2. Zhao Y,
    3. Farooq Z,
    4. Prince MR

    . Immediate allergic reactions to gadolinium-based contrast agents: a systematic review and meta-analysis. Radiology 2018; 286(2):471–482. doi:10.1148/radiol.2017162740

    OpenUrlCrossRefPubMed
56. ↵
    1. Michaely HJ,
    2. Aschauer M,
    3. Deutschmann H, et al

    . Gadobutrol in renally impaired patients: results of the GRIP study. Invest Radiol 2017; 52(1):55–60. doi:10.1097/RLI.0000000000000307

    OpenUrlCrossRef
57. 1. Soyer P,
    2. Dohan A,
    3. Patkar D,
    4. Gottschalk A

    . Observational study on the safety profile of gadoterate meglumine in 35,499 patients: the SECURE study. J Magn Reson Imaging 2017; 45(4):988–997. doi:10.1002/jmri.25486

    OpenUrlCrossRef
58. 1. Tsushima Y,
    2. Awai K,
    3. Shinoda G, et al

    . Post-marketing surveillance of gadobutrol for contrast-enhanced magnetic resonance imaging in Japan. Jpn J Radiol 2018; 36(11):676–685. doi:10.1007/s11604-018-0778-4

    OpenUrlCrossRef
59. 1. Young LK,
    2. Matthew SZ,
    3. Houston JG

    . Absence of potential gadolinium toxicity symptoms following 22,897 gadoteric acid (Dotarem®) examinations, including 3,209 performed on renally insufficient individuals. Eur Radiol 2019; 29(4):1922–1930. doi:10.1007/s00330-018-5737-z

    OpenUrlCrossRef
60. ↵
    1. Bruce R,
    2. Wentland AL,
    3. Haemel AK, et al

    . Incidence of nephrogenic systemic fibrosis using gadobenate dimeglumine in 1423 patients with renal insufficiency compared with gadodiamide. Invest Radiol 2016; 51(11):701–705. doi:10.1097/RLI.0000000000000259

    OpenUrlCrossRefPubMed
61. ↵
    1. European Society of Urogenital Radiology

    . ESUR on contrast media. Accessed September 2020. http://www.esur.org/guidelines/
62. ↵
    1. Zou Z,
    2. Zhang HL,
    3. Roditi GH,
    4. Leiner T,
    5. Kucharczyk W,
    6. Prince MR

    . Nephrogenic systemic fibrosis: review of 370 biopsy-confirmed cases. JACC: Cardiovasc Imaging 2011; 4(11):1206–1216. doi:10.1016/j.jcmg.2011.08.013

    OpenUrlAbstract/FREE Full Text
63. ↵
    1. Kanda T,
    2. Ishii K,
    3. Kawaguchi H,
    4. Kitajima K,
    5. Takenaka D

    . High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology 2014; 270(3):834–841. doi:10.1148/radiol.13131669

    OpenUrlCrossRefPubMed
64. ↵
    1. Kanda T,
    2. Fukusato T,
    3. Matsuda M, et al

    . Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology 2015; 276(1):228–232. doi:10.1148/radiol.2015142690

    OpenUrlCrossRefPubMed
65. ↵
    1. Semelka RC,
    2. Ramalho J,
    3. Vakharia A, et al

    . Gadolinium deposition disease: initial description of a disease that has been around for a while. Magn Reson Imaging 2016; 34(10):1383–1390. doi:10.1016/j.mri.2016.07.016

    OpenUrlCrossRefPubMed
66. ↵
    ACR-ASNR position statement on the use of gadolinium contrast agents. Created May 2016. Accessed September 29, 2020. https://icpme.us/2016ACR/ACR_ASNR_Position_Statement_on_the_Use_of_Gadolinium_Contrast_Agents.pdf